Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Ayumu Matsuoka


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


A. Matsuoka1, A. Mitsuma2, O. Maeda2, N. Tsunoda3, T. Kikumori4, Y. Ando2

Author affiliations

  • 1 Clinical Oncology And Chemotherapy, Nagoya University Hospital, 466-8560 - Nagoya/JP
  • 2 Clinical Oncology And Chemotherapy, Nagoya University Hospital, 458-0014 - Nagoya/JP
  • 3 Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/JP
  • 4 Breast And Endocrine Surgery, Nagoya University Hospital, Nagoya/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 856


Assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) usually depends on subjective grading scales, such as the Common Terminology Criteria for Adverse Events (CTCAE). We previously validated a newly developed point-of-care nerve conduction device (POCD) for the objective and quantitative assessment of CIPN. The present study used this POCD to prospectively track the natural history of paclitaxel (PTX)-related CIPN.


Sural nerve amplitude potentials (SNAP, μV), a quantitative measure of axonal degeneration, and sural nerve conduction velocity (SNCV, m/s), a quantitative measure of the degree of demyelination, were evaluated using a portable, automated POCD (DPN-Check®, Neurometrix Inc., Waltham, MA, USA) in patients with breast cancer scheduled to receive 12 cycles of adjuvant or neoadjuvant weekly PTX, at baseline, after every 2 cycles of PTX (on the first day of the 3rd, 5th, 7th, 11th cycles), and within 1 month after the 12th cycle of PTX. The severity of CIPN was also evaluated according to the CTCAE, version 4.0.


55 patients completed 12 cycles of PTX (median age 51 years, range 32-74; adjuvant/neoadjuvant = 40/15; worst CTCAE G1/G2/G3 = 32/16/7). A total of 49 patients received dose-dense EC (epirubicin + cyclophosphamide) before PTX, and 18 patients with HER2-positive breast cancer received trastuzumab concurrently with PTX. SNAP decreased significantly during each cycle of chemotherapy (repeated ANOVA, P < 0.001), whereas there was no significant change in SNCV (Table). The total sum of SNAP (mean±SD) was 91.7±30.6 in G1, 70.5±30.0 in G2, and 41.4±13.1 in G3. The total sum of SNCV (mean±SD) was 393.5±34.0 in G1, 381.4±39.5 in G2, and 370.1±45.3 in G3. The total SNAP differed significantly according to each CTCAE grade (ANOVA, P < 0.001), whereas the total SNCV did not.Table:

1801P Longitudinal tracking of SNAP and SNCV among 55 patients (mean±SD)

baseline3rd5th7th9th11th1 month after 12th cycle
SNAP (μV)14.2± 6.312.2± 4.811.9± 4.811.4± 5.710.7± 5.09.5± 4.99.0± 4.8
SNCV (m/s)56.6± 4.055.9± 4.956.2± 4.856.2± 4.855.3± 4.455.4± 4.855.4± 4.6


This POCD demonstrated SNAP-dominant neuropathy in patients who received PTX, suggesting axonal degeneration as a mechanism of CIPN.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


Y. Ando: Honoraria (self): Bristol-Myers Squibb Company; Honoraria (self): Sawai Pharmaceutical Co. Ltd.; Research grant / Funding (self): Mochida Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Nippon Kayaku Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.